{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:35:55Z","timestamp":1792791355881,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32HL110837"],"award-info":[{"award-number":["T32HL110837"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.pcad.2023.10.003","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T20:46:05Z","timestamp":1697489165000},"page":"2-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["SGLT inhibitors for improving Healthspan and lifespan"],"prefix":"10.1016","volume":"81","author":[{"given":"James H.","family":"O'Keefe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Weidling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan L.","family":"O'Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Grant","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2023.10.003_bb0005","first-page":"155","article-title":"Training strategies to optimize cardiovascular durability and life expectancy","volume":"120","author":"O\u2019Keefe","year":"2023","journal-title":"Mo Med"},{"key":"10.1016\/j.pcad.2023.10.003_bb0010","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S2213-8587(19)30151-2","article-title":"2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial","volume":"7","author":"Kraus","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pcad.2023.10.003_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2023.07.029","article-title":"Relationship of daily step counts to all-cause mortality and cardiovascular events","author":"Stens","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.10.003_bb0020","first-page":"1","article-title":"Evaluation of off-label rapamycin use to promote healthspan in 333 adults. Online ahead of print","volume":"May 16","author":"Kaeberlein","year":"2023","journal-title":"Geroscience"},{"key":"10.1016\/j.pcad.2023.10.003_bb0025","doi-asserted-by":"crossref","DOI":"10.1111\/acel.12880","article-title":"Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults","volume":"18","author":"Konopka","year":"2019","journal-title":"Aging Cell"},{"key":"10.1016\/j.pcad.2023.10.003_bb0030","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s11357-020-00274-1","article-title":"Effect of rapamycin on aging and age-related diseases-past and future","volume":"43","author":"Selvarani","year":"2021","journal-title":"Geroscience."},{"key":"10.1016\/j.pcad.2023.10.003_bb0035","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1186\/s12889-023-15764-y","article-title":"Comparison of long-term effects of metformin on longevity between people with type 2 diabetes and matched non-diabetic controls","volume":"23","author":"Stevenson-Hoare","year":"2023","journal-title":"BMC Public Health"},{"key":"10.1016\/j.pcad.2023.10.003_bb0040","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1093\/ije\/dyac200","article-title":"Reassessing the evidence of a survival advantage in type 2 diabetes treated with metformin compared with controls without diabetes: a retrospective cohort study","volume":"51","author":"Keys","year":"2022","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.pcad.2023.10.003_bb0045","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the Cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2023.10.003_bb0050","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1479164115616901","article-title":"Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus","volume":"13","author":"Neeland","year":"2016","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.pcad.2023.10.003_bb0055","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019463","article-title":"Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials","volume":"10","author":"Teo","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2023.10.003_bb0060","first-page":"11","article-title":"SGLT2 inhibitors in diabetic and non-diabetic chronic kidney disease","author":"Podesta","year":"2023","journal-title":"Biomedicines."},{"key":"10.1016\/j.pcad.2023.10.003_bb0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine."},{"key":"10.1016\/j.pcad.2023.10.003_bb0070","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1002\/ehf2.13169","article-title":"Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis","volume":"7","author":"Butler","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.pcad.2023.10.003_bb0075","first-page":"3","article-title":"SGLT2 inhibitors in CKD and HFpEF: two new large trials and two new meta-analyses","volume":"30","author":"Mayne","year":"2023","journal-title":"Br J Cardiol"},{"key":"10.1016\/j.pcad.2023.10.003_bb0080","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies G, Consortium SiM-AC-RT","year":"2022","journal-title":"Lancet."},{"key":"10.1016\/j.pcad.2023.10.003_bb0085","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/jdi.13959","article-title":"Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: results from the EMPRISE study","volume":"14","author":"Kim","year":"2023","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.pcad.2023.10.003_bb0090","first-page":"5","article-title":"Canagliflozin extends life span in genetically heterogeneous male but not female mice","author":"Miller","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.pcad.2023.10.003_bb0095","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/dom.14286","article-title":"Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: a meta-analysis of randomized controlled trials","volume":"23","author":"Silverii","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pcad.2023.10.003_bb0100","first-page":"9","article-title":"Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and\/or dipeptidyl peptidase-4 inhibitor: a nationwide study","author":"Suto","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.pcad.2023.10.003_bb0105","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet."},{"key":"10.1016\/j.pcad.2023.10.003_bb0110","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2023.10.003_bb0115","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2023.10.003_bb0120","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(20)30130-3","article-title":"Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study","volume":"8","author":"Kohsaka","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pcad.2023.10.003_bb0125","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2023.10.003_bb0130","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.pcad.2023.10.003_bb0135","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2023.10.003_bb0140","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2023.10.003_bb0145","series-title":"Prevention CfDCa","article-title":"Chronic kidney disease in the United States, 2023","volume":"Vol 2023","year":"2023"},{"key":"10.1016\/j.pcad.2023.10.003_bb0150","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1161\/CIRCULATIONAHA.118.038339","article-title":"Empagliflozin is associated with a lower risk of post-acute heart failure Rehospitalization and mortality","volume":"139","author":"Savarese","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2023.10.003_bb0155","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2023.10.003_bb0160","doi-asserted-by":"crossref","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","article-title":"SGLT-2 inhibitors in heart failure: a review of current evidence","volume":"5","author":"Talha","year":"2023","journal-title":"Int J Heart Fail"},{"key":"10.1016\/j.pcad.2023.10.003_bb0165","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2023.10.003_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.724405","article-title":"Association between SGLT2is and cardiovascular and respiratory diseases: a Meta-analysis of large trials","volume":"12","author":"Yin","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pcad.2023.10.003_bb0175","first-page":"11","article-title":"SGLT2 inhibitors as potential anticancer agents","author":"Basak","year":"2023","journal-title":"Biomedicines."},{"key":"10.1016\/j.pcad.2023.10.003_bb0180","doi-asserted-by":"crossref","first-page":"12299","DOI":"10.1002\/cam4.5927","article-title":"Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in type 2 diabetes mellitus: a population-based study","volume":"12","author":"Chung","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.pcad.2023.10.003_bb0185","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00296-021-04876-6","article-title":"The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis","volume":"41","author":"Cox","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.pcad.2023.10.003_bb0190","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors: benefits versus risk","volume":"15","author":"Jasleen","year":"2023","journal-title":"Cureus."},{"key":"10.1016\/j.pcad.2023.10.003_bb0195","doi-asserted-by":"crossref","first-page":"1158153","DOI":"10.3389\/fendo.2023.1158153","article-title":"Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis","volume":"14","author":"Lai","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.pcad.2023.10.003_bb0200","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/s41416-023-02177-2","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival","volume":"128","author":"Luo","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pcad.2023.10.003_bb0205","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.34067\/KID.0001172021","article-title":"eGFR decline after SGLT2 inhibitor initiation: The tortoise and the hare reimagined","volume":"2","author":"Meraz-Munoz","year":"2021","journal-title":"Kidney360."},{"key":"10.1016\/j.pcad.2023.10.003_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.747620","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. dipeptidyl Peptidase-4 (DPP4) inhibitors for new-onset dementia: a propensity score-matched population-based study with competing risk analysis","volume":"8","author":"Mui","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pcad.2023.10.003_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective effect of SGLT2 inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules."},{"key":"10.1016\/j.pcad.2023.10.003_bb0220","doi-asserted-by":"crossref","DOI":"10.15190\/d.2022.11","article-title":"Sodium glucose co-transport 2 inhibitors for gout treatment","volume":"10","author":"Somagutta","year":"2022","journal-title":"Discoveries (Craiova)"},{"key":"10.1016\/j.pcad.2023.10.003_bb0225","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/jgs.18306","article-title":"Newer glucose-lowering drugs and risk of dementia: a systematic review and meta-analysis of observational studies","volume":"71","author":"Tang","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.pcad.2023.10.003_bb0230","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221086996","article-title":"Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review","volume":"13","author":"Tharmaraja","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.pcad.2023.10.003_bb0235","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1530\/EJE-19-0259","article-title":"Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study","volume":"181","author":"Wium-Andersen","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pcad.2023.10.003_bb0240","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2337\/dc22-1705","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcad.2023.10.003_bb0245","article-title":"Relationship between SGLT-2i and ocular diseases in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.pcad.2023.10.003_bb0250","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/heartjnl-2022-321545","article-title":"Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer","volume":"109","author":"Chiang","year":"2023","journal-title":"Heart."},{"key":"10.1016\/j.pcad.2023.10.003_bb0255","first-page":"10","article-title":"Safety and efficacy of SGLT2 inhibitors: a multiple-treatment meta-analysis of clinical decision indicators","author":"Martinez-Vizcaino","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.pcad.2023.10.003_bb0260","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.pcad.2023.10.003_bb0265","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-020-01048-x","article-title":"The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study","volume":"19","author":"Chen","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pcad.2023.10.003_bb0270","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022222","article-title":"Sodium-glucose co-transporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Pandey","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2023.10.003_bb0275","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cell.2018.09.048","article-title":"Biological functions of autophagy genes: a disease perspective","volume":"176","author":"Levine","year":"2019","journal-title":"Cell."},{"key":"10.1016\/j.pcad.2023.10.003_bb0280","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMra2022774","article-title":"Autophagy in human diseases","volume":"383","author":"Mizushima","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2023.10.003_bb0285","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/cvr\/cvab158","article-title":"The role of autophagy in cardiovascular pathology","volume":"118","author":"Gatica","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pcad.2023.10.003_bb0290","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029777","article-title":"Autophagy-dependent beneficial effects of exercise","volume":"7","author":"Halling","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.pcad.2023.10.003_bb0295","doi-asserted-by":"crossref","first-page":"9887","DOI":"10.1038\/s41598-019-46402-6","article-title":"Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death","volume":"9","author":"Shibusawa","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.pcad.2023.10.003_bb0300","doi-asserted-by":"crossref","first-page":"1197061","DOI":"10.1155\/2022\/1197061","article-title":"Empagliflozin enhances autophagy, mitochondrial biogenesis, and antioxidant defense and ameliorates renal ischemia\/reperfusion in nondiabetic rats","volume":"2022","author":"Ala","year":"2022","journal-title":"Oxidative Med Cell Longev"},{"key":"10.1016\/j.pcad.2023.10.003_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102288","article-title":"Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPKalpha1\/ULK1\/FUNDC1\/mitophagy pathway","volume":"52","author":"Cai","year":"2022","journal-title":"Redox Biol"},{"key":"10.1016\/j.pcad.2023.10.003_bb0310","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1124\/jpet.118.253666","article-title":"Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and antioxidants in diabetic rats","volume":"368","author":"Oshima","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pcad.2023.10.003_bb0315","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/s41401-021-00805-2","article-title":"Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress","volume":"43","author":"Ren","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pcad.2023.10.003_bb0320","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","article-title":"Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pcad.2023.10.003_bb0325","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/CIRCULATIONAHA.119.045561","article-title":"Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance","volume":"141","author":"Packer","year":"2020","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2023.10.003_bb0330","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.yjmcc.2019.02.006","article-title":"The cardiomyocyte \u201credox rheostat\u201d: redox signalling via the AMPK-mTOR axis and regulation of gene and protein expression balancing survival and death","volume":"129","author":"Meijles","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pcad.2023.10.003_bb0335","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1042\/CS20190863","article-title":"Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats","volume":"133","author":"Swe","year":"2019","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.pcad.2023.10.003_bb0340","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100909RR","article-title":"SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney","volume":"36","author":"Ke","year":"2022","journal-title":"FASEB J"},{"key":"10.1016\/j.pcad.2023.10.003_bb0345","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pcad.2023.10.003_bb0350","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2023.10.003_bb0355","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018298","article-title":"Direct cardiac actions of the sodium glucose co-transporter 2 inhibitor empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure-overload heart failure","volume":"10","author":"Li","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2023.10.003_bb0360","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.10.003_bb0365","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/1440-1681.13470","article-title":"Empagliflozin alleviates ethanol-induced cardiomyocyte injury through inhibition of mitochondrial apoptosis via a SIRT1\/PTEN\/Akt pathway","volume":"48","author":"Tian","year":"2021","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pcad.2023.10.003_bb0370","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.pcad.2023.10.003_bb0375","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000520903","article-title":"Effects of sodium-glucose cotransporter 2 on amputation events: a systematic review and meta-analysis of randomized-controlled trials","volume":"107","author":"See","year":"2022","journal-title":"Pharmacology."},{"key":"10.1016\/j.pcad.2023.10.003_bb0380","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous Postmarketing cases","volume":"170","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pcad.2023.10.003_bb0385","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2023.10.003_bb0390","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062023001068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062023001068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:20:57Z","timestamp":1758500457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062023001068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":78,"alternative-id":["S0033062023001068"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2023.10.003","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT inhibitors for improving Healthspan and lifespan","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2023.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}